Clover Health Investments: Real Turnaround, But Already Priced In

Impact · against what's priced in

Clover Health is facing significant downside risks that outweigh its membership growth. The combination of a $120M litigation threat regarding quality bonuses and a projected earnings slump in H2 FY2026 creates a negative outlook.

CLOV−0.30: No priced-in read yet
In context: While 48% YoY membership growth is positive, the $120M at-risk quality bonus revenue and projected negative results for the second half of FY2026 create material financial uncertainty.
Read from the article alone

Clover Health Investments: Real Turnaround, But Already Priced In

cmsNew
medicare advantage▲500%
healthcare
guidance
CLOV
litigation
profitability

Top 2 movers · tap to explore

Clover Health Investments: Real Turnaround, But Already Priced In

What matters in this story

Liquidia Announces Global Settlement Resolving All Pending Litigation with United Therapeutics, Ensuring Continued Commercialization of YUTREPIA in PAH

Clover Health Investments: Real Turnaround, But Already Priced In

What matters in this story

Liquidia Announces Global Settlement Resolving All Pending Litigation with United Therapeutics, Ensuring Continued Commercialization of YUTREPIA in PAH

How each ticker is affected

Track these names every morning.

Johnson & Johnson: Keep Calm And Hold On

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Hims & Hers Health, Inc. of Class Action Lawsuit and Upcoming Deadlines – HIMS

ALHC: Alignment Healthcare Investors Should Contact Block & Leviton to Possibly Recover Losses

Character.AI owes Google and Big Law firms nearly $7M, court filings show

Clover Health Investments: Real Turnaround, But Already Priced In

What matters in this story

Next reads from the same story arc

Liquidia Announces Global Settlement Resolving All Pending Litigation with United Therapeutics, Ensuring Continued Commercialization of YUTREPIA in PAH

Clover Health Investments: Real Turnaround, But Already Priced In

What matters in this story

Next reads from the same story arc

Liquidia Announces Global Settlement Resolving All Pending Litigation with United Therapeutics, Ensuring Continued Commercialization of YUTREPIA in PAH

How each ticker is affected

Track these names every morning.

Johnson & Johnson: Keep Calm And Hold On

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Hims & Hers Health, Inc. of Class Action Lawsuit and Upcoming Deadlines – HIMS

ALHC: Alignment Healthcare Investors Should Contact Block & Leviton to Possibly Recover Losses

Character.AI owes Google and Big Law firms nearly $7M, court filings show